Tags
DePuy, FDA, Food & Drug Administration, Institute of Medicine, Jeffrey Shuren, Medical device, Quality assurance, UNited States
The rate at which FDA issues 483s and warning letters is going up, up, up.
Source: FDA email circular advertising 6th annual FDA Inspections Summit dated 25 Aug 2011.
The agency has already issued 874 letters in fiscal 2011, compared with 673 for all of last year.
FDA’s emphasis on enforcement has led to more, better-educated FDA investigators and more inspections this year.
Both drug- and devicemakers are being held to the highest scrutiny. A review of recent 483s shows investigators ticking off observations — from the simplest to the very complex — like never before:
To a Medical Device Manufacturer, 1/18/2011
“Corrective and preventive actions activities have not been adequately documented. During this inspection, I reviewed 33 complaints … regarding your adjustable hospital bed hand controls … None of the corrective actions dated 2008-2010 contained this documentation.”
To an OTC Contract Drug Manufacturer, 2/15/2011
“Procedures are not followed for the cleaning and maintenance of equipment, including utensils used in the manufacture, processing, packing and holding of a drug product.”
To a Medical Device Manufacturer, 1/27/2011
“Records of complaint investigation do not include required information. Complaint does not include the address of the complainant … does not include the Product Number or Description … does not have the ‘Action/Reply’ section completed …”
To a Drug Manufacturer, 2/11/2011
“Your firm’s QA approved a procedure containing incorrect information on 10/26/2010. Specifically, the procedure references a … System which is no longer in use … (and) incorrectly identified …”
Related articles
- Complaints Surge About Crumbling Artificial Hips (earlsview.com)
- FDA Proposes Guidelines That Clarify Benefit-Risk Determinations For Medical Devices (earlsview.com)
- FDA Loosens Premarket Notification Requirements for 30 Medical Device Types (earlsview.com)
- Medical Devices – Balancing Regulation and Innovation (earlsview.com)
- Hip Implant Complaints Surge, Even as the Dangers Are Studied (earlsview.com)
- Why Are Pharmaceutical Companies Paying The FDA? (earlsview.com)
- IOM Gives FDA The wrong prescription on medical devices & 510(k) (earlsview.com)
- Report could sway FDA device review process (earlsview.com)
- Regulatory Reform Series #5 – FDA Medical Device Regulation: Impact on American Patients, Innovation and Jobs (earlsview.com)
- US Congress Women Rosa L. DeLauro Takes FDA To Task Over Comments re IOM Report (earlsview.com)
What was the FDA’s purpose in writing this lack of information.
Does this article share their concern for people or are they saying ” we are working g the problems; however we are following newer rules, that have been added onto those old one’s that didn’t work.
Somebody must know how to pat shoulders and say great job, and kick a–s.
These warning letters, how much time goes by between sending the warning and the end result. Can I get the real deal information without contacting so many people or groups etc. and can this information be put in a format I can understand?
Probably wishfull thinking.
I am willing to do some of these things, I’m not running for office, just willing to be a pin on a disk as one doctor describes.
Respectfully
Howard Sadwin
Howard
they were advertising some expensive training conference and these paragraphs were the lead in – I though the information was rather interesting.
Earl
Good point Howard.